University of Cincinnati: Bipolar Disorder trials
The registry lists 17 Bipolar Disorder studies with University of Cincinnati as lead sponsor. 0 are open to participants now and 3 have results posted.
Phase 2 1Phase 3 2Phase 4 5No phase 9(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Efficacy and Tolerability of Topiramate in Treatment of Bipolar Mania and Alcohol Use in Adolescents and Young AdultsCompletedNCT00550394Phase 4Results posted
- Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With OlanzapineCompletedNCT00394095Phase 4Results posted
- Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar ManiaCompletedNCT00393978Phase 4Results posted
- Bipolar Disorder Measures in Clinical CareCompletedNCT05300919Not applicable
- Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk YouthCompletedNCT02553161Not applicable
- Neuroimaging Study of Risk Factors for Adolescent Bipolar DisorderCompletedNCT02478788Phase 4
- Mindfulness in Mood Dysregulated YouthCompletedNCT02120937Not applicable
- Mindfulness Based Cognitive Therapy for Youth With Anxiety at Risk for Bipolar DisorderCompletedNCT02090595Not applicable
- Asenapine for Bipolar DepressionTerminatedNCT01807741Phase 2
- Targeted Intervention for Bipolar SmokersStatus unknownNCT01550029Not applicable
- Peroxisomal Defects and Familial Risk for Bipolar DisorderCompletedNCT01237379
- Multimodal Neuroimaging of Treatment Effects in Adolescent ManiaCompletedNCT00893581Not applicable
- Functional and Neurochemical Brain Changes in First-episode Bipolar ManiaCompletedNCT00609193
- Functional and Neurochemical Brain Changes Bipolar DepressionCompletedNCT00608296
- Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar DisorderStatus unknownNCT00608075Phase 4
- A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar DisorderCompletedNCT00232414Phase 3
- An Open-Label Trial of Aripiprazole in Children and Adolescents With Bipolar DisorderCompletedNCT00221416Phase 3